AELMHU and FEDER drive a model to improve the transition to adult care of patients with rare diseases

The FollowER project will develop a proposal to avoid interruptions in follow-up and treatments. Its Institutional Committee includes the participation of the Ministry of Health, scientific societies, and patient organizations

clara foyaca

clara foyaca

Add DEMÓCRATA to Google

Ask FREN

Published

3 minutes

Most read

Elecciones 29N · Encuestas

La media de las encuestas

Media a 18 de noviembre de 2026 · 17 institutos

  • PP31,4 %
  • PSOE27,3 %
  • Vox18,9 %
  • Frente Amplio6,2 %
  • ERC2,4 %
01020304050ene 2024jul 2024ene 2025jul 2025ene 2026jul 2026

Media del último estudio de cada instituto en 30 días y su evolución semanal desde el 23J. Partidos con al menos un 2 %.

Todas las encuestas

Elecciones generales del 29 de noviembre · Demócrata

The Asociación Española de Laboratorios de Medicamentos Huérfanos y Ultrahuérfanos (AELMHU) and the Federación Española de Enfermedades Raras (FEDER) have launched FollowER, a project that seeks to improve the transition from pediatric to adult care for people with rare diseases. The initiative will develop a proposal for a care model to promote continuity of care and coordination among healthcare professionals.

The change of medical teams, specialists, and reference professionals when reaching adulthood can lead to coordination difficulties and interruptions in clinical follow-up and treatments. For these patients and their families, it is a particularly complex stage, in which it is essential to preserve the experience and knowledge accumulated about each case.

Among the project’s challenges is advancing toward common criteria that help reduce differences in care between healthcare centers and autonomous communities, while respecting the needs and circumstances of each person.

"In rare diseases, ensuring continuity of care is as important as advancing diagnosis and access to treatments. Reaching adulthood cannot mean a break in care or a loss of the accumulated knowledge about each patient," notes Clara Foyaca, member of the Board of Directors of AELMHU.

With FollowER, she adds, the association aims to promote "a planned and coordinated process" that will make it possible to respond to patients’ needs at each stage of their lives.

A proposal based on interviews, surveys, and meetings with experts

FollowER includes the development of a document with a comprehensive proposal for an assisted transition model, based on an analysis of the current situation and the main needs of people with rare diseases.

The work will involve a multidisciplinary Technical Committee and will include interviews with healthcare professionals, surveys, and meetings with experts to incorporate different perspectives and care experiences.

The goal is to offer recommendations and guidance that can be applied as a reference for professionals and help improve care across the entire National Health System.

"For people with rare diseases and their families, the transition from pediatric care to adult care can generate a great deal of uncertainty. It is not only a matter of changing specialists, but of ensuring that knowledge about each patient is maintained and that their needs continue to be addressed", explains Mónica Rodríguez, secretary of the Board of FEDER.

"With FollowER, we want to help ensure that no one has to start from scratch when reaching adulthood", she highlights.

Health services, scientific societies and patients participate in the project

The Ministry of Health participates in the Institutional Committee of the initiative together with scientific societies and patient organizations. Among them are the Spanish Association of Pediatrics (AEP), the Platform of Patient Organizations (POP), the Spanish Society for Quality in Care (SECA) and the Spanish Society of Health Executives (SEDISA).

Also participating are the Spanish Society of Hospital Pharmacy (SEFH), the Spanish Society of Family and Community Medicine (semFYC), the Spanish Society of Internal Medicine (SEMI), the Spanish Society of Primary Care Physicians (SEMERGEN) and the Spanish Society of General Practitioners and Family Doctors (SEMG).

This collaboration seeks to incorporate clinical, care-related and social perspectives to develop a proposal adapted to the reality of people with rare diseases.

The driving entities

FEDER brings together 442 patient entities in Spain and works to improve the quality of life of people with rare diseases or who are seeking diagnosis and of their families. Its activity includes direct care, driving research, social transformation and political advocacy, with a person-centered model and equity in access to diagnosis, treatments and comprehensive care.

The federation leads in Spain the World Day for Rare Diseases and is part of EURORDIS, the European rare disease organization.

For its part, AELMHU is a non-profit association that brings together pharmaceutical and biotechnological companies dedicated to investigating, developing and marketing therapies for rare and ultra-rare diseases. It acts as an interlocutor before society, the scientific community and political and health institutions on issues related to orphan drugs, ultra-orphan drugs and other treatments for these conditions.